RVMD Stock Recent News

RVMD LATEST HEADLINES

RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

GlobeNewsWire 2023 May 01
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

GlobeNewsWire 2023 Apr 06
RVMD Stock News Image - Seeking Alpha

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman, President and Chief Executive Officer Steve Kelsey - President of Research and Development Jack Anders - Chief Financial Officer Conference Call Participants Faisal Khurshid - SVB Securities Michael Schmidt - Guggenheim Partners Marc Frahm - Cowen and Company, LLC Eric Joseph - JPMorgan Chase & Co. Benjamin Burnett - Stifel Financial Corp. Alec Stranahan - Bank of America Merrill Lynch Ami Fadia - Needham & Company Jay Olson - Oppenheimer & Co. Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 Year-End 2022 Earnings Conference Call.

Seeking Alpha 2023 Feb 27
RVMD Stock News Image - Zacks Investment Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research 2023 Feb 27
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

GlobeNewsWire 2023 Feb 21
RVMD Stock News Image - Zacks Investment Research

Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research 2023 Feb 02
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be the featured speaker in fireside chats at the Guggenheim Healthcare Talks 2023 Oncology Conference and the SVB Securities Global Biopharma Conference.

GlobeNewsWire 2023 Feb 02
RVMD Stock News Image - Zacks Investment Research

Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research 2023 Jan 12
RVMD Stock News Image - Seeking Alpha

Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy. The company is well-capitalized to continue operations and clinical advancements.

Seeking Alpha 2022 Dec 07
RVMD Stock News Image - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured speaker in fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference and the 5th Annual Evercore ISI HealthCONx Conference.

GlobeNewsWire 2022 Nov 09
10 of 47